Deutsche Bank AG Takes Position in ClearPoint Neuro, Inc. $CLPT

Deutsche Bank AG acquired a new stake in ClearPoint Neuro, Inc. (NASDAQ:CLPT) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 114,795 shares of the company’s stock, valued at approximately $2,048,000.

A number of other institutional investors also recently bought and sold shares of CLPT. SG Americas Securities LLC purchased a new position in ClearPoint Neuro during the first quarter valued at approximately $3,388,000. Prescott Group Capital Management L.L.C. purchased a new stake in ClearPoint Neuro in the 4th quarter worth approximately $2,470,000. Quantinno Capital Management LP boosted its stake in shares of ClearPoint Neuro by 307.4% during the 1st quarter. Quantinno Capital Management LP now owns 51,947 shares of the company’s stock valued at $473,000 after buying an additional 39,195 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of ClearPoint Neuro by 39.6% during the 1st quarter. Bank of New York Mellon Corp now owns 143,747 shares of the company’s stock valued at $1,308,000 after buying an additional 40,741 shares during the period. Finally, Man Group plc grew its holdings in shares of ClearPoint Neuro by 17.4% during the 2nd quarter. Man Group plc now owns 71,884 shares of the company’s stock valued at $858,000 after acquiring an additional 10,674 shares in the last quarter. 30.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently issued reports on CLPT shares. Weiss Ratings reissued a “sell (d-)” rating on shares of ClearPoint Neuro in a research report on Friday, July 17th. Lake Street Capital set a $25.00 price target on ClearPoint Neuro in a report on Tuesday, August 4th. Wall Street Zen cut ClearPoint Neuro from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Stifel Nicolaus set a $22.00 price objective on ClearPoint Neuro in a report on Tuesday, August 4th. Finally, B. Riley Financial raised their price objective on shares of ClearPoint Neuro from $20.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $25.67.

Insider Transactions at ClearPoint Neuro

In other ClearPoint Neuro news, CEO Joseph Burnett sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $19.38, for a total value of $387,600.00. Following the completion of the transaction, the chief executive officer owned 116,842 shares of the company’s stock, valued at $2,264,397.96. This represents a 14.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Timothy T. Richards sold 5,415 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $12.17, for a total value of $65,900.55. Following the completion of the sale, the director owned 87,198 shares of the company’s stock, valued at $1,061,199.66. This represents a 5.85% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 87,258 shares of company stock worth $1,553,964. 6.94% of the stock is owned by company insiders.

ClearPoint Neuro Trading Down 2.4%

Shares of CLPT stock opened at $15.55 on Friday. The firm has a market capitalization of $474.27 million, a P/E ratio of -13.18 and a beta of 1.24. ClearPoint Neuro, Inc. has a 1 year low of $8.27 and a 1 year high of $30.10. The firm’s fifty day simple moving average is $15.97 and its 200 day simple moving average is $13.21. The company has a current ratio of 4.74, a quick ratio of 3.89 and a debt-to-equity ratio of 4.66.

ClearPoint Neuro (NASDAQ:CLPT) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.09). The company had revenue of $10.88 million for the quarter, compared to the consensus estimate of $12.73 million. ClearPoint Neuro had a negative return on equity of 188.09% and a negative net margin of 81.76%.During the same quarter in the previous year, the firm posted ($0.21) EPS. As a group, sell-side analysts predict that ClearPoint Neuro, Inc. will post -1.29 EPS for the current year.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.